US Supreme Court Sets Higher Bar for Patent Infringement in Hikma v. Amarin

Key Facts

The US Supreme Court has clarified the legal standard for induced patent infringement, significantly raising the bar for plaintiffs in intellectual property disputes. In the case of Hikma Pharmaceuticals v. Amarin Pharma, the Court ruled that a complaint must plausibly allege active and affirmative encouragement of infringing use rather than mere interpretative statements. According to reports, this decision aims to prevent patent holders from suing based on passive awareness or contextual inferences, requiring instead concrete evidence of active promotion.

This ruling represents a strategic victory for generic drug manufacturers like Hikma, as it mitigates litigation risks when introducing lower-cost alternatives to the market. Compared to previous precedents such as GSK v. Teva, this clarification provides greater protection for companies using "skinny labels" to carve out patented indications. Per market data, industry peers including Teva and Viatris are closely monitoring these legal shifts due to their direct impact on profit margins within the biopharmaceutical sector.